Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

Get the latest news, views and opinions from Fidelity’s savings and investment experts on using brokerage to invest in ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

According to market research firm GlobalData on the 2nd (local time), Eli Lilly's obesity drug Zepbound is projected to quickly surpass Novo Nordisk's Wegovy in market share and dominate the ...

1 The research firm reached its conclusion based on a recent study that suggests that Zepbound may be more effective at promoting weight loss than Wegovy. The findings also took into consideration ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

In a press release, GlobalData pharma analyst Costanza Alciati said, “From the start, Zepbound emerged as the primary new competitor of Wegovy, and it seems that Eli Lilly has followed in some way ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.